杜皮鲁玛
医学
特应性皮炎
不利影响
皮肤病科
临床试验
重症监护医学
免疫学
药理学
内科学
作者
Elisa Camela,Anna Rita Giampetruzzi,Ornella De Pità,Sabatino Pallotta,Filomena Russo
标识
DOI:10.1080/14740338.2024.2326480
摘要
Dupilumab is an effective treatment for AD, showing favorable safety profile since no routine laboratory monitoring is recommended. However, several cutaneous and extracutaneous AEs have been reported in real-life setting expanding the pool emerged from clinical trials. In detail, dupilumab may determine de-novo onset or exacerbation of preexisting conditions, whose pathogenesis is still unclear and seems to involve Th1/Th2 and Th2/Th17 immune-response imbalance. Also, the heterogeneity and the variable onset time of AEs with respect to dupilumab initiation warrant a thorough patients' history collection and strict short- and long-term monitoring. Finally, the most appropriate management of patients with AEs related to dupilumab should take into consideration efficacy for AD as well as severity and nature of the AE, available treatment and patients' preferences.
科研通智能强力驱动
Strongly Powered by AbleSci AI